MacroGenics Provides Corporate Progress Update and Third Quarter 2013 Financial Results ROCKVILLE, Md., Nov. 12, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based...

MacroGenics to Present Pre-Clinical Data on Targeting CD123-Positive Leukemic Stem Cells at the 55th ASH Annual Meeting ROCKVILLE, Md., Nov. 11, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX), a clinical-stage biopharmaceutical company focused on discovering and developing innovative monoclonal antibody-based...

MacroGenics DART Therapeutic Selected by Boehringer Ingelheim as a Bi-Specific Pre-Clinical Development Candidate ROCKVILLE, Md., Nov. 11, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that Boehringer Ingelheim has nominated a bi-specific antibody therapeutic candidate generated by...

MacroGenics Announces Timing for Third Quarter 2013 Financial Results and Conference Call ROCKVILLE, Md., Nov. 5, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced that on Tuesday, November 12, 2013, the Company will release its financial results for the third...

MacroGenics Announces Closing of Initial Public Offering and Full-Exercise of Over-Allotment Option ROCKVILLE, Md., Oct. 16, 2013 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq:MGNX) today announced the closing of its initial public offering of 5,750,000 shares of its common stock, including 750,000...